Cargando…

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data

Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yanan, Perlin, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712954/
https://www.ncbi.nlm.nih.gov/pubmed/32998224
http://dx.doi.org/10.3390/jof6040192
_version_ 1783618484137099264
author Zhao, Yanan
Perlin, David S.
author_facet Zhao, Yanan
Perlin, David S.
author_sort Zhao, Yanan
collection PubMed
description Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies.
format Online
Article
Text
id pubmed-7712954
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77129542020-12-04 Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data Zhao, Yanan Perlin, David S. J Fungi (Basel) Review Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies. MDPI 2020-09-28 /pmc/articles/PMC7712954/ /pubmed/32998224 http://dx.doi.org/10.3390/jof6040192 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhao, Yanan
Perlin, David S.
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title_full Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title_fullStr Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title_full_unstemmed Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title_short Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
title_sort review of the novel echinocandin antifungal rezafungin: animal studies and clinical data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712954/
https://www.ncbi.nlm.nih.gov/pubmed/32998224
http://dx.doi.org/10.3390/jof6040192
work_keys_str_mv AT zhaoyanan reviewofthenovelechinocandinantifungalrezafunginanimalstudiesandclinicaldata
AT perlindavids reviewofthenovelechinocandinantifungalrezafunginanimalstudiesandclinicaldata